Suppr超能文献

人类中枢神经系统中可溶性淀粉样前体蛋白代谢物的昼夜节律。

Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system.

机构信息

Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America.

Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.

出版信息

PLoS One. 2014 Mar 19;9(3):e89998. doi: 10.1371/journal.pone.0089998. eCollection 2014.

Abstract

The amyloid-β (Aβ) protein is diurnally regulated in both the cerebrospinal fluid and blood in healthy adults; circadian amplitudes decrease with aging and the presence of cerebral Aβ deposits. The cause of the Aβ diurnal pattern is poorly understood. One hypothesis is that the Amyloid Precursor Protein (APP) is diurnally regulated, leading to APP product diurnal patterns. APP in the central nervous system is processed either via the β-pathway (amyloidogenic), generating soluble APP-β (sAPPβ) and Aβ, or the α-pathway (non-amyloidogenic), releasing soluble APP-α (sAPPα). To elucidate the potential contributions of APP to the Aβ diurnal pattern and the balance of the α- and β- pathways in APP processing, we measured APP proteolytic products over 36 hours in human cerebrospinal fluid from cognitively normal and Alzheimer's disease participants. We found diurnal patterns in sAPPα, sAPPβ, Aβ40, and Aβ42, which diminish with increased age, that support the hypothesis that APP is diurnally regulated in the human central nervous system and thus results in Aβ diurnal patterns. We also found that the four APP metabolites were positively correlated in all participants without cerebral Aβ deposits. This positive correlation suggests that the α- and β- APP pathways are non-competitive under normal physiologic conditions where APP availability may be the limiting factor that determines sAPPα and sAPPβ production. However, in participants with cerebral Aβ deposits, there was no correlation of Aβ to sAPP metabolites, suggesting that normal physiologic regulation of cerebrospinal fluid Aβ is impaired in the presence of amyloidosis. Lastly, we found that the ratio of sAPPβ to sAPPα was significantly higher in participants with cerebral Aβ deposits versus those without deposits. Therefore, the sAPPβ to sAPPα ratio may be a useful biomarker for cerebral amyloidosis.

摘要

淀粉样蛋白-β(Aβ)蛋白在健康成年人的脑脊液和血液中都存在昼夜节律调节;昼夜节律振幅随年龄的增长和脑内 Aβ 沉积的存在而降低。Aβ 昼夜节律模式的原因尚不清楚。一种假设是淀粉样前体蛋白(APP)存在昼夜节律调节,导致 APP 产物的昼夜节律模式。中枢神经系统中的 APP 要么通过β途径(淀粉样生成)进行处理,生成可溶性 APP-β(sAPPβ)和 Aβ,要么通过α途径(非淀粉样生成)进行处理,释放可溶性 APP-α(sAPPα)。为了阐明 APP 对 Aβ 昼夜节律模式的潜在贡献以及 APP 加工中α-和β-途径的平衡,我们在认知正常和阿尔茨海默病参与者的人脑脊液中测量了 APP 蛋白水解产物超过 36 小时。我们发现 sAPPα、sAPPβ、Aβ40 和 Aβ42 存在昼夜节律模式,随着年龄的增长而减少,这支持了 APP 在人类中枢神经系统中存在昼夜节律调节的假说,从而导致了 Aβ 的昼夜节律模式。我们还发现,在没有脑 Aβ 沉积的所有参与者中,四种 APP 代谢物呈正相关。这种正相关表明,在正常生理条件下,α-和β-APP 途径是非竞争性的,在这种情况下,APP 的可用性可能是决定 sAPPα 和 sAPPβ 产生的限制因素。然而,在有脑 Aβ 沉积的参与者中,Aβ 与 sAPP 代谢物之间没有相关性,这表明在淀粉样变性的情况下,脑脊液 Aβ 的正常生理调节受损。最后,我们发现,有脑 Aβ 沉积的参与者的 sAPPβ 与 sAPPα 的比值明显高于没有沉积的参与者。因此,sAPPβ 与 sAPPα 的比值可能是脑淀粉样变性的有用生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e661/3960093/a813ddfe80b5/pone.0089998.g001.jpg

相似文献

1
Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system.
PLoS One. 2014 Mar 19;9(3):e89998. doi: 10.1371/journal.pone.0089998. eCollection 2014.
2
Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
Brain Res. 2013 Jun 4;1513:117-26. doi: 10.1016/j.brainres.2013.03.019. Epub 2013 Mar 27.
3
CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.
J Neurosci. 2014 Jun 11;34(24):8336-46. doi: 10.1523/JNEUROSCI.0540-14.2014.
4
Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer's disease.
Alzheimers Res Ther. 2020 Aug 12;12(1):96. doi: 10.1186/s13195-020-00664-9.
5
Heteromers of amyloid precursor protein in cerebrospinal fluid.
Mol Neurodegener. 2015 Jan 8;10:2. doi: 10.1186/1750-1326-10-2.
6
Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System.
JAMA Neurol. 2017 Feb 1;74(2):207-215. doi: 10.1001/jamaneurol.2016.4202.
7
Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.
Neuromolecular Med. 2012 Mar;14(1):65-73. doi: 10.1007/s12017-012-8171-4. Epub 2012 Feb 18.
8
Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid.
Alzheimers Dement. 2012 Jul;8(4):304-11. doi: 10.1016/j.jalz.2011.04.009. Epub 2011 Nov 4.
9
Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
J Neurosci Res. 2011 Jun;89(6):822-32. doi: 10.1002/jnr.22618. Epub 2011 Mar 23.
10
Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment.
Aging Clin Exp Res. 2022 Feb;34(2):341-347. doi: 10.1007/s40520-021-01935-7. Epub 2021 Jul 20.

引用本文的文献

1
Salivary levels of amyloid beta reflect brain amyloid beta burden in cognitively-normal older adults.
J Prev Alzheimers Dis. 2025 Jun 9:100216. doi: 10.1016/j.tjpad.2025.100216.
2
P-tau217 and other blood biomarkers of dementia: variation with time of day.
Transl Psychiatry. 2024 Sep 13;14(1):373. doi: 10.1038/s41398-024-03084-7.
5
Role of sleep in neurodegeneration: the consensus report of the 5th Think Tank World Sleep Forum.
Neurol Sci. 2024 Feb;45(2):749-767. doi: 10.1007/s10072-023-07232-7. Epub 2023 Dec 13.
8
It's complicated: The relationship between sleep and Alzheimer's disease in humans.
Neurobiol Dis. 2020 Oct;144:105031. doi: 10.1016/j.nbd.2020.105031. Epub 2020 Jul 29.
9
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome.
Alzheimers Dement (Amst). 2020 Jul 9;12(1):e12057. doi: 10.1002/dad2.12057. eCollection 2020.
10
Deciphering the neuroprotective and neurogenic potential of soluble amyloid precursor protein alpha (sAPPα).
Cell Mol Life Sci. 2020 Jun;77(12):2315-2330. doi: 10.1007/s00018-019-03404-x. Epub 2020 Jan 20.

本文引用的文献

1
Sleep drives metabolite clearance from the adult brain.
Science. 2013 Oct 18;342(6156):373-7. doi: 10.1126/science.1241224.
2
Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
Brain Res. 2013 Jun 4;1513:117-26. doi: 10.1016/j.brainres.2013.03.019. Epub 2013 Mar 27.
3
β-amyloid dynamics in human plasma.
Arch Neurol. 2012 Dec;69(12):1591-7. doi: 10.1001/archneurol.2012.18107.
4
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology.
Sci Transl Med. 2012 Sep 5;4(150):150ra122. doi: 10.1126/scitranslmed.3004291.
6
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011.
7
Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid.
Alzheimers Dement. 2012 Jul;8(4):304-11. doi: 10.1016/j.jalz.2011.04.009. Epub 2011 Nov 4.
8
Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system.
Arch Neurol. 2012 Jan;69(1):51-8. doi: 10.1001/archneurol.2011.235. Epub 2011 Sep 12.
10
Biology and pathophysiology of the amyloid precursor protein.
Mol Neurodegener. 2011 Apr 28;6(1):27. doi: 10.1186/1750-1326-6-27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验